Literature DB >> 29029125

Vaccine Prevention of Respiratory Syncytial Virus Infection in Older Adults: The Work Continues.

Joanne M Langley1,2,3.   

Abstract

Entities:  

Keywords:  Respiratory Syncytial Virus; older adults; vaccine

Mesh：

Substances：

Year:  2017        PMID： 29029125      PMCID： PMC5853301          DOI： 10.1093/infdis/jix504

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  13 in total

Review 1.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

Review 2.  The Primary Outcome Fails - What Next?

Authors:  Stuart J Pocock; Gregg W Stone
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

3.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

4.  Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

Authors:  Ann R Falsey; Edward E Walsh; Jose Capellan; Stefan Gravenstein; Maria Zambon; Eddy Yau; Geoffrey J Gorse; Robert Edelman; Frederick G Hayden; Janet E McElhaney; Kathleen M Neuzil; Kristen L Nichol; Eric A F Simões; Peter F Wright; Valérie M-P Sales
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

5.  Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.

Authors:  Jeffrey N Roberts; Barney S Graham; Ruth A Karron; Flor M Munoz; Ann R Falsey; Larry J Anderson; V Marshall; Sonnie Kim; Judy A Beeler
Journal:  Vaccine       Date:  2016-08-25       Impact factor: 3.641

6.  Factors that may impact on immunosenescence: an appraisal.

Authors:  Joseph Ongrádi; Valéria Kövesdi
Journal:  Immun Ageing       Date:  2010-06-14       Impact factor: 6.400

7.  A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Authors:  Joanne M Langley; Valerie Sales; Allison McGeer; Roland Guasparini; Gerald Predy; William Meekison; Minran Li; Jose Capellan; Elaine Wang
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

Review 8.  The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review.

Authors:  Ann D Colosia; Jin Yang; Eric Hillson; Josephine Mauskopf; Catherine Copley-Merriman; Vivek Shinde; Jeffrey Stoddard
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

9.  Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.

Authors:  Louis Fries; Vivek Shinde; Jeffrey J Stoddard; D Nigel Thomas; Eloi Kpamegan; Hanxin Lu; Gale Smith; Somia P Hickman; Pedro Piedra; Gregory M Glenn
Journal:  Immun Ageing       Date:  2017-04-12       Impact factor: 6.400

10.  Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom.

Authors:  Douglas M Fleming; Robert J Taylor; Roger L Lustig; Cynthia Schuck-Paim; François Haguinet; David J Webb; John Logie; Gonçalo Matias; Sylvia Taylor
Journal:  BMC Infect Dis       Date:  2015-10-23       Impact factor: 3.090
View more
  2 in total

1.  Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009-2017.

Authors:  Allen L Nazareno; David J Muscatello; Robin M Turner; James G Wood; Hannah C Moore; Anthony T Newall
Journal:  Influenza Other Respir Viruses       Date:  2022-06-30       Impact factor: 5.606

Review 2.  The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.

Authors:  Jing Shan; Philip N Britton; Catherine L King; Robert Booy
Journal:  Influenza Other Respir Viruses       Date:  2021-03-25       Impact factor: 4.380
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.